Back as Strides managing director, founder Arun Kumar is confident of reversing a slide in profits via a recalibration strategy that saw the company exit Canada and a few European markets. Meanwhile, eyes are on the fallout of a CRO that serviced Strides apart from Sandoz, Teva and more getting caught in CHMP and FDA’s crosshairs.
Founder Arun Kumar is back in the driver’s seat at Strides Pharma Science Limited and at the first analyst meet post resumption of his role as managing director, outlined a recalibration strategy that saw the company exit Canada and a few European markets while continuing to be upbeat about the US.
In FY23, conserving cash will likely be high on the agenda as the company tries to fight repercussions of the...
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
